Global Medtech Guidance Tracker: February 2022
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.
You may also be interested in...
A 20-day consultation on the risk classification of medical devices intended for the Malaysia market ends on 28 February
The highest risk IVDs, which fall into class D, are subject to additional testing criteria. New guidance explains how the notified body acts − not only as reviewer but also as facilitator so additional safety and performance guarantees can be sought.
The European pharmaceutical industry federation, EFPIA, says its member companies are not looking for shortcuts to develop and validate digital biomarkers, but want help from regulators to create the right evidence.